| 标题 |
426P A multicenter, randomized, double-blind, phase II study of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) to evaluate the safety and efficacy of a daily oral starting dose of 18 mg vs 24 mg |
| 网址 | |
| DOI | |
| 其它 |
期刊:Annals of Oncology 作者:M. Brose; Yury Panaseykin; B. Konda; C. Fouchardière; B. Hughes; et al 出版日期:2020-11-01 |
| 求助人 | |
| 下载 | 该求助完结已超 24 小时,文件已从服务器自动删除,无法下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)